GPR75 recombinant proteins and antibodies

G Protein-Coupled Receptor 75 (GPR75), a member of the GPCR family, was first identified by Tarttelin et al. in 1999. It plays a significant role in various diseases, including obesity, cancer, and metabolic syndrome, making it one of the most promising targets for weight loss therapy.
GPR75’s emergence as a novel target for obesity treatment is primarily based on a groundbreaking study published by Regeneron in the journal Science in July 2021. This study analyzed the relationship between rare genetic mutations and body mass index (BMI) by conducting whole-exome sequencing on 645,000 individuals from the UK, USA, and Mexico. The researchers identified 16 nonsynonymous genetic mutations associated with BMI. Notably, they found that truncating GPR75 mutations occurred at a rate of 0.004%, with heterozygous mutations leading to a lower BMI by 1.8 kg/m², a weight reduction of 5.4 kg, and a 54% lower risk of obesity. Additionally, in vivo validation studies in mice demonstrated that GPR75 knockout mice had lower body weight, blood glucose levels, and insulin levels. For more details on the GPR75 target and its signaling pathways, click here >>

DIMA BIOTECH is a biotechnology company specializing in the preclinical development of druggable targets and related services. It currently offers a comprehensive range of products and services for the GPR75 target. These include:

Products:

• Full-length active protein
• ECD (extracellular domain) active protein
• Flow cytometry-validated monoclonal antibodies

Services:

• Custom anti-mouse antibody development services
• Antibody humanization
• Affinity maturation services

To accelerate the development of GPR75-based biotherapies, DIMA BIOTECH has also established a single B cell clone library for the GPR75 target, enabling the fastest delivery of lead antibody molecules within 28 days.